Adverse Effects

Biomarkers

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head & Neck Cancer

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematologic Oncology

Hormone-related Cancers

Immunotherapy

Vaccines

Infection

Leukemia

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Lung Cancer

Hodgkin Lymphoma

Lymphoma

Melanoma

Mesothelioma

Neuroendocrine Tumors

Oncology

Pediatric Cancers

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Surgery

Thyroid Cancer

News

Clinical Topics

Global Bulletin

All News

Approval Alert

Media

2 Minute Drill

Around the Practice

Between the Lines

Breaking Barriers

Face Off

From All Angles

Meeting of the Minds

Morning Rounds

OncView

Podcasts

Readout 360

Training Academy

Treatment Algorithms with the Oncology Brothers

Conferences

Publications

All Journals

Editorial Board

For Authors

Year in Review

Events

Frontline Forum

Satellite Sessions

CME/CE

Resources

Contemporary Concepts

Awareness Month

Interactive Tools

Nurse Practitioners/Physician's Assistants

Partners

Career Center

Subscribe

Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Editorial

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Cancer Network

Facebook

LinkedIn

Spotlight

Around the Practice 

Journal

Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice

Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Clinical

Acute Myeloid Leukemia

Genitourinary Cancer

Gynecologic Cancer

Hematology

Skin Cancer

1rem

View

Precision Oncology in AML: Molecular Insights, Maintenance Strategies, and Emerging Therapies

Video Series

Face-Off

Clinical Scenario: TP53- Mutant AML

Videos

Panelists discuss how emerging therapies like CC-486, venetoclax, and menin inhibitors are reshaping treatment strategies for relapsed and refractory acute myeloid leukemia while debating the role of posttransplant maintenance and personalized approaches based on genetic mutations such as 

Panelists discuss how the all-oral regimen of oral azacitidine and venetoclax offers a promising treatment option for newly diagnosed and relapsed/refractory acute myeloid leukemia, highlighting its potential to improve patient outcomes and simplify treatment administration.

All Oral Regimen of Oral Azacitidine and Venetoclax for Newly Diagnosed and Relapsed/Refractory AML

Panelists discuss how the updated results and longer follow-up from the AUGMENT-101 study of revumenib demonstrate its potential to improve outcomes in patients with relapsed/refractory KMT2Ar acute leukemia, offering a promising new option in this challenging subset of acute myeloid leukemia.

AUGMENT-101 Updated Results and Longer Follow-Up of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia

Panelists debate the best posttransplant follow-up approach for acute myeloid leukemia, weighing the benefits of maintenance therapy vs close monitoring with regular laboratory testing to optimize patient outcomes and minimize long-term risks.

Debate: What Is the Best Posttransplant Follow-Up - Maintenance vs Close Monitoring With Laboratory Testing

Panelists debate the treatment of relapsed/recurrent acute myeloid leukemia, comparing the potential of menin inhibitors to standard-of-care therapies, including chemotherapy and BCL2 inhibitors, in improving patient outcomes.

Debate: Treating Patients With Relapsed/Recurrent AML - MENIN Inhibitors vs Standard of Care

Panelists discuss the clinical scenario of newly diagnosed acute myeloid lymphoma (AML) with an NPM1 mutation, exploring treatment strategies and key considerations for managing this patient population.

Clinical Scenario: Newly Diagnosed AML With an NPM1 Mutation

Panelists discuss the clinical scenario of TP53-mutant  acute myeloid lymphoma (AML), focusing on treatment approaches and key challenges in managing this high-risk patient group.

CancerNetwork® Face-Off

is a live event hosted by CancerNetwork® in which renowned cancer institutions go head-to-head in a friendly debate on the latest data in a specific therapeutic area. The Face-Off program provides the ideal platform for a meaningful dialogue and data review among fellows and attending junior oncologists, as well as other key stakeholders.

Clinical Scenario: TP53- Mutant AML

EP: 1.All Oral Regimen of Oral Azacitidine and Venetoclax for Newly Diagnosed and Relapsed/Refractory AML

EP: 2.AUGMENT-101 Updated Results and Longer Follow-Up of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia

EP: 3.Debate: What Is the Best Posttransplant Follow-Up - Maintenance vs Close Monitoring With Laboratory Testing

EP: 4.Debate: Treating Patients With Relapsed/Recurrent AML - MENIN Inhibitors vs Standard of Care

EP: 5.Clinical Scenario: Newly Diagnosed AML With an NPM1 Mutation

EP: 6.Clinical Scenario: TP53- Mutant AML

Newsletter